Pediatric Exclusivity 90-Day Review Can Be “Difficult” Target – Kweder

FDA sometimes is challenged to meet the deadline for completing the review of whether a drug sponsor's clinical trials in children qualify a product for pediatric exclusivity, Office of New Drugs Deputy Director Sandra Kweder indicated May 22